Article
Gastrointestinal Stromal Tumors: The GIST of Precision Medicine.
Trends in cancer - 1 Jan 2018
Mei Lin, Smith Steven C, Faber Anthony C, Trent Jonathan, Grossman Steven R, Stratakis Constantine A, Boikos Sosipatros A
Abstract excerpt
The discovery of activated KIT mutations in gastrointestinal (GI) stromal tumors (GISTs) in 1998 triggered a sea change in our understanding of these tumors and has ushered in a new paradigm for the use of molecular genetic diagnostics to guide targeted therapies. KIT and PDGFRA mutations account for 85-90% of GISTs; subsequent genetic studies have led to the identification of mutation/epimutation of additional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.